StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note released on Friday morning. The firm issued a hold rating on the stock.

EKSO has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Ekso Bionics in a report on Tuesday, March 4th. Lake Street Capital lowered their target price on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th.

Ekso Bionics Trading Down 9.7 %

Shares of Ekso Bionics stock opened at $0.38 on Friday. Ekso Bionics has a 1 year low of $0.34 and a 1 year high of $1.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The business has a 50 day moving average price of $0.50 and a 200 day moving average price of $0.72. The company has a market capitalization of $9.38 million, a P/E ratio of -0.58 and a beta of 1.33.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). The company had revenue of $5.09 million during the quarter, compared to analysts’ expectations of $5.05 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. Sell-side analysts anticipate that Ekso Bionics will post -0.48 EPS for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.